Digest Network Come funziona
Network
/
Società
Ja
Non verificato

Janux Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

19 comunicati stampa

Guarda tutti i comunicati
01/12/2025
Web e Social Network
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
24/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
06/11/2025
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
07/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Mercato azionario
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
05/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
24/07/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Web e Social Network
Industria
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
17/07/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
15/05/2025
Mercato del lavoro
Oncologia
Salute
Sanità
Farmaceutica
Biotecnologia
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
08/05/2025
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
05/05/2025
Industria
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0